{"title":"Evaluating the Compositional Quality of Probiotics Containing Bacillus clausii in India.","authors":"Dhanasekhar Kesavelu, Sridhar Ganpathy, Pramod Jog, Bhaswati Acharya, Vivek Saxena, Nivedita Telang, Nilesh Gaikwad","doi":"10.1007/s12325-025-03289-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The quality of probiotics is crucial for their effectiveness and safety. Many studies have found discrepancies between the claimed and the actual content of microorganisms in probiotics. However, only few studies have assessed the quality of these products in India. This study aimed to evaluate the quality of various probiotics containing Bacillus clausii in India.</p><p><strong>Methods: </strong>Eleven commercially available probiotics containing Bacillus clausii were selected: Enterogermina® (reference product), Bifilac clausii™, Entromax®, Progermina™, Entroflora™, Novogermina™, Tufpro™, Gutgermina®, Eco-All™, Entero clausi™, and Medogermina®. Suspensions were cultured and subcultured in selective media to identify Bacillus clausii colonies. Purity, viable spore load, and antibiotic resistance were assessed.</p><p><strong>Results: </strong>The assessed parameters varied significantly among the probiotics. Enterogermina® was contamination-free, with a spore count of 2 billion/5 mL and showed resistance to all tested antibiotics. Progermina™ and Eco-all™ had higher spore counts than claimed but were contaminated with Bacillus cereus. Contaminants were found in all products except Enterogermina® and Medogermina®. Most of the products showed no antibiotic resistance.</p><p><strong>Conclusion: </strong>The study revealed significant differences in the quality of probiotics on the Indian market, highlighting concerns about their potency and safety. Stringent quality control is necessary to ensure consumer safety and help healthcare professionals make informed decisions.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-025-03289-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The quality of probiotics is crucial for their effectiveness and safety. Many studies have found discrepancies between the claimed and the actual content of microorganisms in probiotics. However, only few studies have assessed the quality of these products in India. This study aimed to evaluate the quality of various probiotics containing Bacillus clausii in India.
Methods: Eleven commercially available probiotics containing Bacillus clausii were selected: Enterogermina® (reference product), Bifilac clausii™, Entromax®, Progermina™, Entroflora™, Novogermina™, Tufpro™, Gutgermina®, Eco-All™, Entero clausi™, and Medogermina®. Suspensions were cultured and subcultured in selective media to identify Bacillus clausii colonies. Purity, viable spore load, and antibiotic resistance were assessed.
Results: The assessed parameters varied significantly among the probiotics. Enterogermina® was contamination-free, with a spore count of 2 billion/5 mL and showed resistance to all tested antibiotics. Progermina™ and Eco-all™ had higher spore counts than claimed but were contaminated with Bacillus cereus. Contaminants were found in all products except Enterogermina® and Medogermina®. Most of the products showed no antibiotic resistance.
Conclusion: The study revealed significant differences in the quality of probiotics on the Indian market, highlighting concerns about their potency and safety. Stringent quality control is necessary to ensure consumer safety and help healthcare professionals make informed decisions.
期刊介绍：
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
